

Arturo Cesaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9305093/publications.pdf>

Version: 2024-02-01

63
papers

1,196
citations

331642

21
h-index

414395

32
g-index

67
all docs

67
docs citations

67
times ranked

1725
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. Heart Failure Clinics, 2022, 18, 39-49.	2.1	18
2	The Biological Role of Vitamins in Athletesâ€™ Muscle, Heart and Microbiota. International Journal of Environmental Research and Public Health, 2022, 19, 1249.	2.6	27
3	Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. Neurology International, 2022, 12, 102-108.	0.5	1
4	Early-onset MINOCA: Prognostic implications and considerations for practice. International Journal of Cardiology, 2022, 354, 14-16.	1.7	1
5	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European Journal of Preventive Cardiology, 2022, 29, 832-841.	1.8	23
6	Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical Implications. Current Vascular Pharmacology, 2022, 20, 318-320.	1.7	0
7	Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovascular Diabetology, 2022, 21, 77.	6.8	76
8	The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. Inflammopharmacology, 2022, 30, 1143-1151.	3.9	4
9	Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 3574.	2.4	2
10	Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. Future Cardiology, 2021, 17, 647-654.	1.2	8
11	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	2.0	21
12	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. International Journal of Cardiology, 2021, 327, 176-182.	1.7	10
13	Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuloplasty guided by low dose of radiation: a case report and brief overview. General Thoracic and Cardiovascular Surgery, 2021, 69, 364-366.	0.9	0
14	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. International Journal of Environmental Research and Public Health, 2021, 18, 904.	2.6	32
15	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Internal and Emergency Medicine, 2021, 16, 1583-1591.	2.0	9
16	Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. Pediatric Cardiology, 2021, 42, 1133-1140.	1.3	9
17	Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target. Monaldi Archives for Chest Disease, 2021, 91, .	0.6	0
18	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences, 2021, 22, 5863.	4.1	48

#	ARTICLE	IF	CITATIONS
19	SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction. Critical Care, 2021, 25, 217.	5.8	35
20	Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Research and Clinical Practice, 2021, 178, 108959.	2.8	42
21	Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter. International Journal of Cardiology, 2021, 339, 243-245.	1.7	2
22	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases, 2021, 16, 381.	2.7	12
23	Advanced Heart Failure in Special Populationâ€”Pediatric Age. Heart Failure Clinics, 2021, 17, 673-683.	2.1	6
24	Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Reviews in Cardiovascular Medicine, 2021, 22, 755.	1.4	45
25	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. Journal of Cardiovascular Medicine, 2021, 22, 151-161.	1.5	53
26	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. International Journal of Cardiology, 2021, 345, 7-13.	1.7	35
27	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
28	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. Heart Failure Clinics, 2021, 18, 177-188.	2.1	14
29	Coronary stent thickness: thinner is (always) better for all lesions?. Journal of Cardiovascular Medicine, 2021, 22, 26-28.	1.5	1
30	Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. Diagnostics, 2021, 11, 2144.	2.6	11
31	596<i>f</i>Multidisciplinary in-depth investigation in a young athlete suffering from syncope caused by myocardial bridge. European Heart Journal Supplements, 2021, 23, .	0.1	0
32	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
33	341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients. European Heart Journal Supplements, 2021, 23, .	0.1	0
34	785â€fSodiumâ€glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk. European Heart Journal Supplements, 2021, 23, .	0.1	0
35	Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. European Journal of Preventive Cardiology, 2020, 27, 556-558.	1.8	39
36	Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C677T polymorphism. European Journal of Preventive Cardiology, 2020, 27, 1906-1908.	1.8	16

#	ARTICLE	IF	CITATIONS
37	Childhood obesity: an overview of laboratory medicine, exercise and microbiome. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1385-1406.	2.3	11
38	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. Cardiology Clinics, 2020, 38, 575-588.	2.2	5
39	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. Archives of Cardiovascular Diseases, 2020, 113, 642-651.	1.6	9
40	Cardiac involvement in systemic sclerosis: “early diagnosis” “early management” approach. European Journal of Preventive Cardiology, 2020, 27, 1873-1875.	1.8	1
41	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. Journal of Cardiovascular Pharmacology, 2020, 76, 173-180.	1.9	31
42	Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. International Journal of Environmental Research and Public Health, 2020, 17, 9424.	2.6	23
43	Methicillin-Resistant Staphylococcus aureus: Risk for General Infection and Endocarditis Among Athletes. Antibiotics, 2020, 9, 332.	3.7	8
44	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. BioFactors, 2020, 46, 367-380.	5.4	46
45	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. Current Vascular Pharmacology, 2020, 18, 294-301.	1.7	8
46	How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-AMI Study. Clinical Cardiology, 2019, 42, 1113-1120.	1.8	5
47	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). American Journal of Cardiology, 2019, 124, 1662-1668.	1.6	20
48	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. Journal of Electrocardiology, 2019, 57, 44-54.	0.9	7
49	Quality Of Life Improvement In High And Very High Cardiovascular Risk Patients Treated With Pcsk9 Inhibitors. Atherosclerosis, 2019, 287, e199.	0.8	0
50	Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. Expert Review of Cardiovascular Therapy, 2019, 17, 435-447.	1.5	24
51	Laboratory medicine: health evaluation in elite athletes. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1450-1473.	2.3	25
52	Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Internal and Emergency Medicine, 2019, 14, 621-625.	2.0	37
53	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. Journal of Cardiovascular Medicine, 2018, 19, 83-90.	1.5	13
54	Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients. Journal of Cardiovascular Medicine, 2018, 19, 75-77.	1.5	34

#	ARTICLE	IF	CITATIONS
55	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.	1.8	8
56	Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 951-962.	1.5	24
57	Lipoprotein(a) screening in patients with premature myocardial infarction: Clinical role and impact on decision-making. <i>Atherosclerosis</i> , 2018, 275, e161.	0.8	1
58	Letter by CalabrÃ² et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" <i>Circulation</i> , 2018, 138, 218-219.	1.6	0
59	Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis. <i>Minerva Cardioangiologica</i> , 2018, 66, 659-670.	1.2	8
60	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. <i>Interventional Medicine & Applied Science</i> , 2017, 9, 123-135.	0.2	2
61	Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 266-272.	1.2	8
62	The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.	3.0	173
63	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 488-498.	1.2	28